Nanotherapeutics interfere with cellular redox homeostasis for highly improved photodynamic therapy

Biomaterials. 2019 Dec:224:119500. doi: 10.1016/j.biomaterials.2019.119500. Epub 2019 Sep 17.

Abstract

Redox homeostasis inside malignant cells is a defense mechanism against the reactive oxygen species (ROS)-induced therapy means, but little importance has been paid to this innate barrier. The present study intends to make cancer cells more sensitive to the ROS-induced therapy by disturbing cellular redox homeostasis. To verify this concept, a porous metal-organic framework (MOF) serves not only as the photodynamic therapy (PDT) agent but also as the carrier to transport alkaloid piperlongumine (PL), a thioredoxin reductase (TrxR) inhibitor used to disturb cellular redox homeostasis. The PL-loaded MOF was further coated with cancer cell membranes to gain homologous tumor-targeting capability. Inside tumor cells, the released PL can effectively block the TrxR-mediated ROS elimination pathway. The resultant data show that compared to traditional PDT alone, the combination of PDT and TrxR inhibition causes profound promotions in cellular ROS level by about 1.6 times, in cytotoxicity by about 2 times, and in cellular apoptosis/necrosis rate by about 3 times. Consequently, this strategy based on the interference with cellular redox homeostasis has demonstrated high potency to improve the anticancer PDT performance, adumbrating a new way to boost the power of ROS-induced therapy.

Keywords: Metal-organic framework; Photodynamic therapy; Reactive oxygen species; Redox homeostasis; Thioredoxin reductase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3 Cells
  • Activating Transcription Factor 4 / metabolism
  • Animals
  • Cell Line, Tumor
  • Dioxolanes / therapeutic use
  • Drug Liberation
  • Homeostasis*
  • Humans
  • Hydrogen-Ion Concentration
  • Metal-Organic Frameworks / chemistry
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles / therapeutic use*
  • Oxidation-Reduction
  • Photochemotherapy*
  • Reactive Oxygen Species / metabolism
  • Thioredoxin-Disulfide Reductase / metabolism

Substances

  • ATF4 protein, human
  • Dioxolanes
  • Metal-Organic Frameworks
  • Reactive Oxygen Species
  • Activating Transcription Factor 4
  • Thioredoxin-Disulfide Reductase
  • piperlongumine